

# Nicolas Sergeant

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7873989/publications.pdf>

Version: 2024-02-01

108  
papers

7,374  
citations

44069

48  
h-index

56724

83  
g-index

128  
all docs

128  
docs citations

128  
times ranked

9503  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1. <i>Journal of Neurology</i> , 2022, , .	3.6	2
2	Reversal of RNA toxicity in myotonic dystrophy via a decoy RNA-binding protein with high affinity for expanded CUG repeats. <i>Nature Biomedical Engineering</i> , 2022, 6, 207-220.	22.5	16
3	Impaired Glucose Homeostasis in a Tau Knock-In Mouse Model. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, 841892.	2.9	4
4	Impact of chronic doxycycline treatment in the APP/PS1 mouse model of Alzheimer's disease. <i>Neuropharmacology</i> , 2022, 209, 108999.	4.1	3
5	A $\gamma$ -Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration. <i>Frontiers in Pharmacology</i> , 2021, 12, 679335.	3.5	2
6	Identification of proAKAP4 concentration variations in dromedary sperm and their correlation with monthly semen parameters. <i>Reproduction and Fertility</i> , 2021, 2, 268-279.	1.8	6
7	Pharmacomodulations around an anti-Alzheimer drug-candidate. <i>European Journal of Medicinal Chemistry Reports</i> , 2021, 4, 100020.	1.4	0
8	Mass spectrometry reveals distinct proteomic profiles in high- and low-quality stallion spermatozoa. <i>Reproduction</i> , 2020, 160, 695-707.	2.6	23
9	New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2019, 129, 217-233.	4.4	21
10	Expression, localization, and concentration of A-kinase anchor protein 4 (AKAP4) and its precursor (proAKAP4) in equine semen: Promising marker correlated to the total and progressive motility in thawed spermatozoa. <i>Theriogenology</i> , 2019, 131, 52-60.	2.1	33
11	A Kinase Anchor Protein 4 Is Vulnerable to Oxidative Adduction in Male Germ Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 319.	3.7	29
12	Myotonic Dystrophy: an RNA Toxic Gain of Function Tauopathy?. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1184, 207-216.	1.6	10
13	New phenylaniline derivatives as modulators of amyloid protein precursor metabolism. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2151-2164.	3.0	6
14	$\beta$ -Amyloid Precursor Protein Intracellular Domain Controls Mitochondrial Function by Modulating Phosphatase and Tensin Homolog-Induced Kinase 1 Transcription in Cells and in Alzheimer Mice Models. <i>Biological Psychiatry</i> , 2018, 83, 416-427.	1.3	45
15	Contribution of the Endosomal-Lysosomal and Proteasomal Systems in Amyloid- $\beta$ Precursor Protein Derived Fragments Processing. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 435.	3.7	24
16	A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect $\beta$ -secretase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 159, 104-125.	5.5	16
17	Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APP <sup>swE</sup> /PS1 <sup>dE9</sup> Mouse Model of Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 235.	2.9	72
18	A-kinase anchor protein 4 precursor (proAKAP4) in human spermatozoa. <i>Andrology</i> , 2018, 6, 854-859.	3.5	31

#	ARTICLE	IF	CITATIONS
19	Concentration of proAKAP4 as a pertinent read-out of sperm quality in mammals. <i>Animal Reproduction Science</i> , 2018, 194, e24.	1.5	5
20	Defining the human sperm microtubulome: an integrated genomics approach. <i>Biology of Reproduction</i> , 2017, 96, 93-106.	2.7	15
21	Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology. <i>Molecular Psychiatry</i> , 2017, 22, 874-883.	7.9	98
22	Two-Dimensional Electrophoresis Protocols to Analyze the Microtubule-Associated Tau Proteins from Several Biological Sources. <i>Methods in Molecular Biology</i> , 2017, 1523, 251-261.	0.9	3
23	Development of a MBNL1 decoy-based gene therapy for myotonic dystrophy. <i>Neuromuscular Disorders</i> , 2017, 27, S181.	0.6	0
24	[P4116]: FRONTOTEMPORAL LOBAR DEGENERATIONS, RNAOPATHY LEADING TO PROTEINOPATHIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1301.	0.8	0
25	Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1033-1043.	2.6	104
26	Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation. <i>Acta Neuropathologica Communications</i> , 2016, 4, 74.	5.2	18
27	Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. <i>Journal of Proteome Research</i> , 2016, 15, 667-676.	3.7	91
28	A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. <i>Molecular Psychiatry</i> , 2016, 21, 97-107.	7.9	145
29	Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. <i>Scientific Reports</i> , 2015, 5, 9659.	3.3	100
30	Regulation of human MAPT gene expression. <i>Molecular Neurodegeneration</i> , 2015, 10, 28.	10.8	132
31	Chloroquine and Chloroquinoline Derivatives as Models for the Design of Modulators of Amyloid Peptide Precursor Metabolism. <i>ACS Chemical Neuroscience</i> , 2015, 6, 559-569.	3.5	35
32	Human Spermatozoa as a Model for Detecting Missing Proteins in the Context of the Chromosome-Centric Human Proteome Project. <i>Journal of Proteome Research</i> , 2015, 14, 3606-3620.	3.7	55
33	MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain. <i>Cell Reports</i> , 2015, 12, 1159-1168.	6.4	120
34	miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation <i>in vivo</i> . <i>Human Molecular Genetics</i> , 2015, 24, 6721-6735.	2.9	177
35	Mutant huntingtin alters Tau phosphorylation and subcellular distribution. <i>Human Molecular Genetics</i> , 2015, 24, 76-85.	2.9	73
36	RBFOX1 Cooperates with MBNL1 to Control Splicing in Muscle, Including Events Altered in Myotonic Dystrophy Type 1. <i>PLoS ONE</i> , 2014, 9, e107324.	2.5	45

#	ARTICLE	IF	CITATIONS
37	Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy. <i>Frontiers in Molecular Neuroscience</i> , 2014, 6, 57.	2.9	69
38	Consensus Brain-derived Protein, Extraction Protocol for the Study of Human and Murine Brain Proteome Using Both 2D-DIGE and Mini 2DE Immunoblotting. <i>Journal of Visualized Experiments</i> , 2014, . .	0.3	6
39	Tau exon 2 responsive elements deregulated in myotonic dystrophy type I are proximal to exon 2 and synergistically regulated by MBNL1 and MBNL2. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 654-664.	3.8	23
40	Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke. <i>Proteome Science</i> , 2014, 12, 24.	1.7	17
41	O1-09-02: DETECTION AND QUANTIFICATION OF THE TAU PROTEIN AND ITS ISOFORMS IN THE CSF OF ALZHEIMER'S DISEASE PATIENTS USING MASS SPECTROMETRY. , 2014, 10, P147-P147.		0
42	MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway. <i>Oncotarget</i> , 2014, 5, 754-763.	1.8	23
43	Immunodetection of Tau microtubule-associated protein in human sperm and testis. <i>Asian Journal of Andrology</i> , 2014, 16, 927.	1.6	8
44	MBNL1 gene variants as modifiers of disease severity in myotonic dystrophy type 1. <i>Journal of Neurology</i> , 2013, 260, 998-1003.	3.6	12
45	Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker. <i>Neurobiology of Aging</i> , 2013, 34, 757-769.	3.1	16
46	NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a tau transgenic model. <i>Aging Cell</i> , 2013, 12, 11-23.	6.7	64
47	Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour. <i>Brain</i> , 2013, 136, 957-970.	7.6	64
48	Synaptic protein dysregulation in myotonic dystrophy type 1. <i>Rare Diseases (Austin, Tex )</i> , 2013, 1, e25553.	1.8	14
49	A New Decision Tree Combining Abeta 1-42 and p-Tau Levels in Alzheimer's Diagnosis. <i>Current Alzheimer Research</i> , 2013, 10, 357-364.	1.4	19
50	Potential Contribution of Exosomes to the Prion-Like Propagation of Lesions in Alzheimer's Disease. <i>Frontiers in Physiology</i> , 2012, 3, 229.	2.8	93
51	Tau Phosphorylation and Sevoflurane Anesthesia. <i>Survey of Anesthesiology</i> , 2012, 56, 176.	0.1	5
52	Tau Phosphorylation and Sevoflurane Anesthesia. <i>Anesthesiology</i> , 2012, 116, 779-787.	2.5	195
53	Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THY <sub>Tau22</sub> Mouse Model: A Suitable Therapeutic Approach. <i>Current Alzheimer Research</i> , 2012, 9, 397-405.	1.4	173
54	Clinical, Neuropathological, and Biochemical Characterization of the Novel Tau Mutation P332S. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 741-749.	2.6	25

#	ARTICLE	IF	CITATIONS
55	MicroRNAs and the Regulation of Tau Metabolism. International Journal of Alzheimer's Disease, 2012, 2012, 1-6.	2.0	65
56	Nuclear Tau, a Key Player in Neuronal DNA Protection. Journal of Biological Chemistry, 2011, 286, 4566-4575.	3.4	342
57	O3-05-01: Nuclear tau protects DNA in stress condition. , 2011, 7, S507-S507.		0
58	Tau Pathology. Advances in Neurobiology, 2011, , 83-132.	1.8	1
59	Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by overexpression of CELF2 but not by MBNL1 silencing. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 732-742.	3.8	45
60	Contribution of Multivesicular Bodies to the Prion-Like Propagation of Lesions in Alzheimer's Disease. , 2011, , .		0
61	Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nature Medicine, 2011, 17, 720-725.	30.7	299
62	AN 88-YEAR OLD WOMAN WITH LONG-LASTING PARKINSONISM. Brain Pathology, 2011, 21, 465-468.	4.1	0
63	Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. Neurobiology of Disease, 2011, 43, 486-494.	4.4	137
64	MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Human Molecular Genetics, 2011, 20, 4016-4024.	2.9	136
65	Analysis of Exonic Regions Involved in Nuclear Localization, Splicing Activity, and Dimerization of Muscleblind-like-1 Isoforms. Journal of Biological Chemistry, 2011, 286, 16435-16446.	3.4	62
66	From tau phosphorylation to tau aggregation: what about neuronal death?. Biochemical Society Transactions, 2010, 38, 967-972.	3.4	87
67	Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Human Molecular Genetics, 2010, 19, 3959-3969.	2.9	285
68	Two-Dimensional Electrophoresis of Tau Mutants Reveals Specific Phosphorylation Pattern Likely Linked to Early Tau Conformational Changes. PLoS ONE, 2009, 4, e4843.	2.5	25
69	Early Tau Pathology Involving the Septo-Hippocampal Pathway in a Tau Transgenic Model: Relevance to Alzheimers Disease. Current Alzheimer Research, 2009, 6, 152-157.	1.4	50
70	Epstein-Barr Virus Protein EB2 Contains an N-Terminal Transferable Nuclear Export Signal That Promotes Nucleocytoplasmic Export by Directly Binding TAP/NXF1. Journal of Virology, 2009, 83, 12759-12768.	3.4	31
71	Altered splicing of Tau in DM1 is different from the foetal splicing process. FEBS Letters, 2009, 583, 675-679.	2.8	9
72	Characterization of the interaction between A $\beta$ 1-42 and glyceraldehyde phosphodehydrogenase. Journal of Peptide Science, 2008, 14, 755-762.	1.4	27

#	ARTICLE	IF	CITATIONS
73	Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Review of Proteomics, 2008, 5, 207-224.	3.0	242
74	Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: Two individual consequences of CUG trinucleotide repeats. Experimental Neurology, 2008, 210, 467-478.	4.1	47
75	Tau as a biomarker of neurodegenerative diseases. Biomarkers in Medicine, 2008, 2, 363-384.	1.4	83
76	Alkalizing Drugs Induce Accumulation of Amyloid Precursor Protein By-products in Luminal Vesicles of Multivesicular Bodies. Journal of Biological Chemistry, 2007, 282, 18197-18205.	3.4	176
77	Involvement of -site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8167-8172.	7.1	107
78	Protein Kinase CK2 Phosphorylation of EB2 Regulates Its Function in the Production of Epstein-Barr Virus Infectious Viral Particles. Journal of Virology, 2007, 81, 11850-11860.	3.4	30
79	Intracellular pH regulates amyloid precursor protein intracellular domain accumulation. Neurobiology of Disease, 2007, 25, 686-696.	4.4	78
80	Brain-specific change in alternative splicing of Tau exon 6 in myotonic dystrophy type 1. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 460-467.	3.8	50
81	Pin1 allows for differential Tau dephosphorylation in neuronal cells. Molecular and Cellular Neurosciences, 2006, 32, 155-160.	2.2	68
82	ETR-3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I. Journal of Neuroscience Research, 2006, 84, 852-859.	2.9	44
83	Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in A $\beta$ amyloid load. Journal of Neurochemistry, 2005, 93, 330-338.	3.9	45
84	Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiology of Disease, 2005, 20, 625-637.	4.4	82
85	Tau protein as a differential biomarker of tauopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 179-197.	3.8	262
86	A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24. Brain, 2004, 127, 1979-1992.	7.6	38
87	P3-031 A novel A $\beta$ -amyloid <sub>42</sub> index in cerebrospinal fluid for specific determination of Alzheimer's disease. Neurobiology of Aging, 2004, 25, S360.	3.1	0
88	Massive CA1/2 Neuronal Loss with Intraneuronal and N-Terminal Truncated A $\beta$ <sub>42</sub> Accumulation in a Novel Alzheimer Transgenic Model. American Journal of Pathology, 2004, 165, 1289-1300.	3.8	375
89	Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology. Acta Neuropathologica, 2003, 105, 89-97.	7.7	42
90	Diffuse form of argyrophilic grain disease: a new variant of four-repeat tauopathy different from limbic argyrophilic grain disease. Acta Neuropathologica, 2003, 106, 575-583.	7.7	38

#	ARTICLE	IF	CITATIONS
91	In vitro models of age-related neurodegenerative disorders. <i>Experimental Gerontology</i> , 2003, 38, 1309-1317.	2.8	9
92	Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. <i>Journal of Neurochemistry</i> , 2003, 85, 1581-1591.	3.9	196
93	Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. <i>Brain</i> , 2002, 125, 801-811.	7.6	157
94	Tau aggregation in the hippocampal formation: an ageing or a pathological process?. <i>Experimental Gerontology</i> , 2002, 37, 1291-1296.	2.8	88
95	Argyrophilic grain disease and Alzheimer's disease are distinguished by their different distribution of tau protein isoforms. <i>Acta Neuropathologica</i> , 2002, 104, 425-434.	7.7	79
96	Progressive decrease of amyloid precursor protein carboxy terminal fragments (APP-CTFs), associated with tau pathology stages, in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2002, 81, 663-672.	3.9	61
97	Abnormal Tau phosphorylation of the Alzheimer-type also occurs during mitosis. <i>Journal of Neurochemistry</i> , 2002, 83, 412-420.	3.9	65
98	Pin1 : A Therapeutic Target in Alzheimer Neurodegeneration. <i>Journal of Molecular Neuroscience</i> , 2002, 19, 275-288.	2.3	38
99	Paradoxical phosphorylation of the serine 199 on tau proteins from young individuals. <i>NeuroReport</i> , 2001, 12, 3177-3181.	1.2	9
100	Hepatocyte growth factor/scatter factor stimulates migration of rat mammary fibroblasts through both mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt pathways. <i>FEBS Journal</i> , 2001, 268, 4423-4429.	0.2	42
101	Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2001, 6, 253-273.	2.7	67
102	Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. <i>Human Molecular Genetics</i> , 2001, 10, 2143-2155.	2.9	237
103	Rapid Tau Protein Dephosphorylation and Differential Rephosphorylation during Cardiac Arrest-Induced Cerebral Ischemia and Reperfusion. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 543-549.	4.3	53
104	Stimulation of DNA Synthesis and Cell Proliferation of Human Mammary Myoepithelial-like Cells by Hepatocyte Growth Factor/Scatter Factor Depends on Heparan Sulfate Proteoglycans and Sustained Phosphorylation of Mitogen-activated Protein Kinases p42/44. <i>Journal of Biological Chemistry</i> , 2000, 275, 17094-17099.	3.4	36
105	Fibroblast Growth Factor-2 Stimulation of p42/44MAPK Phosphorylation and I $\beta$ B Degradation Is Regulated by Heparan Sulfate/Heparin in Rat Mammary Fibroblasts. <i>Journal of Biological Chemistry</i> , 2000, 275, 33905-33910.	3.4	65
106	Pathological Tau Phenotypes: The Weight of Mutations, Polymorphisms, and Differential Neuronal Vulnerabilities. <i>Annals of the New York Academy of Sciences</i> , 2000, 920, 107-114.	3.8	22
107	Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. <i>FEBS Letters</i> , 1998, 433, 201-204.	2.8	104
108	Specific Pathological Tau Protein Variants Characterize Pick's Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 159-168.	1.7	204